Similar articles for PMID: 38423782

Year	Number of Results
1999	1
2001	1
2002	1
2004	2
2005	4
2006	1
2008	3
2009	2
2010	2
2011	1
2012	5
2013	7
2014	5
2015	9
2016	11
2017	8
2018	8
2019	10
2020	13
2021	22
2022	11
2023	9
2024	30

1

Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study.

Eigler C, McDougall L, Bauman A, Bernhardt P, Hentschel M, Blackham KA, Nicolas G, Fani M, Wild D, Cordier D. Eigler C, et al. J Nucl Med. 2024 Apr 1;65(4):573-579. doi: 10.2967/jnumed.123.266817. J Nucl Med. 2024. PMID: 38423782 Clinical Trial.

2

Multimodal Imaging of 2-Cycle PRRT with ¹⁷⁷Lu-DOTA-JR11 and ¹⁷⁷Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model.

Albrecht J, Exner S, Grötzinger C, Prasad S, Konietschke F, Beindorff N, Kühl AA, Prasad V, Brenner W, Koziolek EJ. Albrecht J, et al. J Nucl Med. 2021 Mar;62(3):393-398. doi: 10.2967/jnumed.120.250274. Epub 2020 Aug 28. J Nucl Med. 2021. PMID: 32859703 Free PMC article.

3

Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.

Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, Fischer R, Rivier JE, Reubi JC, Maecke HR, Weber WA. Wild D, et al. J Nucl Med. 2014 Aug;55(8):1248-52. doi: 10.2967/jnumed.114.138834. Epub 2014 Jun 24. J Nucl Med. 2014. PMID: 24963127 Free article.

4

First-in-Humans Study of the SSTR Antagonist ¹⁷⁷Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy.

Baum RP, Zhang J, Schuchardt C, Müller D, Mäcke H. Baum RP, et al. J Nucl Med. 2021 Nov;62(11):1571-1581. doi: 10.2967/jnumed.120.258889. Epub 2021 Mar 5. J Nucl Med. 2021. PMID: 33674401 Free PMC article.

5

Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.

Dalm SU, Nonnekens J, Doeswijk GN, de Blois E, van Gent DC, Konijnenberg MW, de Jong M. Dalm SU, et al. J Nucl Med. 2016 Feb;57(2):260-5. doi: 10.2967/jnumed.115.167007. Epub 2015 Oct 29. J Nucl Med. 2016. PMID: 26514177 Free article.

6

Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy.

Boursier C, Zaragori T, Bros M, Bordonne M, Melki S, Taillandier L, Blonski M, Roch V, Marie PY, Karcher G, Imbert L, Verger A. Boursier C, et al. Eur Radiol. 2023 Oct;33(10):7089-7098. doi: 10.1007/s00330-023-09697-8. Epub 2023 May 6. Eur Radiol. 2023. PMID: 37148355 Review.

7

Estimation of Absorbed Doses of Indigenously Produced "Direct-route" Lutetium-177-[¹⁷⁷Lu]Lu-DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added [¹⁷⁷Lu]Lu-DOTA-TATE and the Trend with Multiple Cycles.

Kamaldeep, Loharkar S, Das T, Basu S, Banerjee S. Kamaldeep, et al. Cancer Biother Radiopharm. 2022 Apr;37(3):214-225. doi: 10.1089/cbr.2021.0340. Epub 2021 Dec 15. Cancer Biother Radiopharm. 2022. PMID: 34910891

8

Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog ¹⁷⁷Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors.

Zhang J, Wang H, Jacobson O, Cheng Y, Niu G, Li F, Bai C, Zhu Z, Chen X. Zhang J, et al. J Nucl Med. 2018 Nov;59(11):1699-1705. doi: 10.2967/jnumed.118.209841. Epub 2018 Apr 13. J Nucl Med. 2018. PMID: 29653971 Free PMC article. Clinical Trial.

9

Safety and efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTA⁰-Tyr³-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors.

Kobayashi N, Takano S, Ito K, Sugiura M, Ogawa M, Takeda Y, Okubo N, Suzuki A, Tokuhisa M, Kaneta T, Utsunomiya D, Hata M, Inoue T, Hosono M, Kinuya S, Ichikawa Y. Kobayashi N, et al. Ann Nucl Med. 2021 Dec;35(12):1332-1341. doi: 10.1007/s12149-021-01674-9. Epub 2021 Sep 17. Ann Nucl Med. 2021. PMID: 34533700 Free PMC article. Clinical Trial.

10

A phase I/II study of the safety and efficacy of [¹⁷⁷Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.

Wild D, Grønbæk H, Navalkissoor S, Haug A, Nicolas GP, Pais B, Ansquer C, Beauregard JM, McEwan A, Lassmann M, Pennestri D, Volteau M, Lenzo NP, Hicks RJ. Wild D, et al. Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):183-195. doi: 10.1007/s00259-023-06383-1. Epub 2023 Sep 18. Eur J Nucl Med Mol Imaging. 2023. PMID: 37721581 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

136 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Similar articles for PMID: 38423782

136 results

Results by year